From BigGo Finance · BigGo Finance · · 50s
Candel Therapeutics Stock Plunges 39% as FDA Filing Delayed
Candel Therapeutics shares dropped 39% after FDA filing for prostate cancer therapy pushed to mid-2027.
In brief
Candel Therapeutics shares dropped 39% after FDA filing for prostate cancer therapy pushed to mid-2027. Candel Therapeutics stock fell 39% in after-hours trading as FDA filing for prostate cancer therapy delayed to mid-2027. Originally reported by BigGo Finance.
Stock Plunge
Candel Therapeutics shares fell 39% in after-hours trading after FDA filing for prostate cancer therapy delayed to mid-2027.
Financial Results
Company reported third-quarter net loss of $21.9 million, up from $11.3 million a year earlier.
FDA Timeline Shift
FDA filing for aglatimagene now expected in mid-2027 instead of fourth quarter of 2026.
Cash Position
Cash of $203.1 million expected to fund operations through second quarter of 2028.
CEO Statement
CEO Paul Peter Tak said company is well positioned to execute operating plan into Q2 2028.
“We believe we are well positioned to execute our operating plan into Q2 2028”
What it means
Candel Therapeutics stock fell 39% in after-hours trading as FDA filing for prostate cancer therapy delayed to mid-2027.
